Compare CDMOs with ADC manufacturing capabilities for bioconjugation, cytotoxic payload synthesis, and integrated antibody-drug conjugate production.
65 companies listed
Antibody-drug conjugate (ADC) manufacturing combines three distinct manufacturing disciplines: monoclonal antibody production (biologics), cytotoxic payload and linker synthesis (high-potency small molecule chemistry), and bioconjugation (attaching the payload to the antibody). Few CDMOs can handle all three under one roof, making ADC CDMO selection particularly complex.
Bioconjugation is the differentiating step. The process of attaching cytotoxic payloads to antibodies via chemical linkers requires: controlled reaction conditions in contained environments (the payloads are potent), precise drug-to-antibody ratio (DAR) control, conjugation chemistry expertise (cysteine, lysine, site-specific), and analytical methods for DAR characterization. CDMOs with established conjugation platforms save significant development time.
Germany
Vetter Pharma is a leading global Contract Development and Manufacturing Organization specializing in aseptic fill-and-finish services for injectable drug products. Headquartered in Ravensburg, Germany, Vetter operates as an independent, family-owned business with over 75 years of experience.
Italy
AbbVie Contract Manufacturing is an embedded CMO within AbbVie, providing third-party contract manufacturing services for over 40 years across 12 locations in the US and Europe. They offer services spanning antibody drug conjugates, aseptic fill/finish, biologics (mAbs and derivatives), custom API, eye care, hot melt extrusion, HPAPI, and oral solid dose manufacturing.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.